drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic, off-the-shelf CAR T-cell therapy targeting CD19; engineered donor T cells mediate cytotoxic killing of CD19-positive B cells via perforin/granzyme and cytokine release pathways.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells engineered with a CD19-specific chimeric antigen receptor recognize CD19 on B-lineage cells and, upon engagement, activate T-cell effector functions to kill CD19-positive cells via perforin/granzyme-mediated cytolysis and cytokine release, leading to depletion of malignant B cells.
drug_name
CD19-UCART
nct_id_drug_ref
NCT05381181